Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novartis withdraws application to extend marketing authorization for Zometa

Nov. 22, 2007

Vivus initiates phase III CONQUER trial of Qnexa in obese patients

Nov. 22, 2007

Actelion patents novel dual orexin OX1/OX2 receptor antagonists for eating disorders

Nov. 21, 2007

BioXell initiates phase IIa trial of elocalcitol for male infertility

Nov. 21, 2007

European Commission endorses positive opinion of EMEA for sanofi-aventis' Acomplia

Nov. 21, 2007

Genta reports positive data from phase I clinical trial of G-4544 for accelerated bone loss

Nov. 20, 2007

Novel antiobesity agents described in recent patent literature

Nov. 20, 2007

Insmed positioned to initiate clinical studies of follow-on biologics products

Nov. 20, 2007

The Juvenile Diabetes Research Foundation and Lilly fund research in diabetes biomarkers

Nov. 19, 2007

Amylin reports positive results from phase IIa study of pramlintide and metreleptin

Nov. 19, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Roche secures CE mark for Alzheimer’s blood test
BioWorld
Roche Holding AG secured CE marking for the Elecsys plasma phosphorylated-tau 217 blood test designed to rule in and rule out amyloid pathology, a hallmark of...